This topic contains a solution. Click here to go to the answer

Author Question: Why have most CDS systems not shown to significantly impact patient outcomes in clinical trials, ... (Read 91 times)

jake

  • Hero Member
  • *****
  • Posts: 538
Why have most CDS systems not shown to significantly impact patient outcomes in clinical trials, despite the fact that a majority of systems have been shown to significantly improve care processes?
 
  a. CDS systems have not been evaluated in clinical trials.
  b. Very few studies have assessed the impact of CDS systems on patient outcomes.
  c. Many CDS system evaluation trials are underpowered to detect changes in care outcomes.
  d. CDS systems have been implemented and evaluated in too many diverse institutions.

Question 2

Which group would have a financial incentive to implement CDS?
 
  a. A community hospital
  b. An inner-city clinic
  c. A national insurer
  d. Depends on CDS and healthcare payment model



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

nyrave

  • Sr. Member
  • ****
  • Posts: 344
Answer to Question 1

ANS: C
The sample sizes of many CDS system evaluation studies were too small or conducted with too short of a time period to detect changes in care outcomes.

Answer to Question 2

ANS: D
Whether a particular stakeholder group has a financial incentive to implement CDS depends on the specific CDS under consideration and the governing healthcare payment model in place.




jake

  • Member
  • Posts: 538
Reply 2 on: Jul 8, 2018
Gracias!


laurnthompson

  • Member
  • Posts: 334
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

The people with the highest levels of LDL are Mexican American males and non-Hispanic black females.

Did you know?

Parkinson's disease is both chronic and progressive. This means that it persists over a long period of time and that its symptoms grow worse over time.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

IgA antibodies protect body surfaces exposed to outside foreign substances. IgG antibodies are found in all body fluids. IgM antibodies are the first type of antibody made in response to an infection. IgE antibody levels are often high in people with allergies. IgD antibodies are found in tissues lining the abdomen and chest.

Did you know?

The first monoclonal antibodies were made exclusively from mouse cells. Some are now fully human, which means they are likely to be safer and may be more effective than older monoclonal antibodies.

For a complete list of videos, visit our video library